CytoImmune Therapeutics
Clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies and providing clinical cell manufacturing. The organization conducts preclinical and early clinical development of allogeneic, off-the-shelf NK cell products, operates cell and viral manufacturing sites (including an ISO 7 cleanroom facility in Puerto Rico), and pursues regulatory filings and collaborations with academic partners.
Industries
Nr. of Employees
medium (51-250)
CytoImmune Therapeutics
Patents
Products
TRACK-NK platform
Engineered, tumor-reactive allogeneic NK cell platform combining CAR expression and secretion of IL-15 and BiKE molecules to enable direct tumor targeting and immune stimulation.
CYTO-102 (CI-NK)
Cytokine-induced NK cell therapy intended for clinical evaluation in non-small cell lung cancer as a proof-of-concept program.
CYTO NK-203 (PSCA-directed CAR NK)
Allogeneic cord blood–derived CAR NK cell product directed against prostate stem cell antigen (PSCA) and engineered to secrete IL-15 for solid tumor indications (preclinical to clinical progression reported).
TRACK-NK platform
Engineered, tumor-reactive allogeneic NK cell platform combining CAR expression and secretion of IL-15 and BiKE molecules to enable direct tumor targeting and immune stimulation.
CYTO-102 (CI-NK)
Cytokine-induced NK cell therapy intended for clinical evaluation in non-small cell lung cancer as a proof-of-concept program.
CYTO NK-203 (PSCA-directed CAR NK)
Allogeneic cord blood–derived CAR NK cell product directed against prostate stem cell antigen (PSCA) and engineered to secrete IL-15 for solid tumor indications (preclinical to clinical progression reported).
Services
Process development, technology transfer, GMP-style manufacturing, viral transduction, cryopreservation, and release testing for autologous and allogeneic cell therapies.
Perform manufacturing under services agreements for third-party cell therapy products.
Process development, technology transfer, GMP-style manufacturing, viral transduction, cryopreservation, and release testing for autologous and allogeneic cell therapies.
Perform manufacturing under services agreements for third-party cell therapy products.
Expertise Areas
- Cell therapy manufacturing
- NK cell engineering and CAR-NK development
- CMC and process development for biologics and cell therapies
- Preclinical pharmacology and animal models
Key Technologies
- Retroviral transduction
- Chimeric antigen receptor (CAR) engineering
- Secreted IL-15 expression
- Bispecific killer engager (BiKE) secretion
News & Updates
Announcement of first patient dosed in a Phase 1 trial conducted in collaboration with an academic partner to evaluate an off-the-shelf engineered NK cell therapy for NSCLC.
Announcement of opening a clinical cell manufacturing facility in Toa Baja to support cell therapy manufacturing activities.
Reference to a peer-reviewed study demonstrating that PDGF-D signaling activates NK cells and enhances IL-15–mediated NK cell survival; cited as foundational data relevant to engineering NK cells with secreted IL-15.
Summary of preclinical work showing freeze-thaw preserved CAR NK cells targeting PSCA prolonged survival in mouse models of metastatic pancreatic cancer.
Licensed CAR NK cell technologies and patent applications from an academic research center to develop an NK cell therapy portfolio.
Announcement of first patient dosed in a Phase 1 trial conducted in collaboration with an academic partner to evaluate an off-the-shelf engineered NK cell therapy for NSCLC.
Announcement of opening a clinical cell manufacturing facility in Toa Baja to support cell therapy manufacturing activities.
Reference to a peer-reviewed study demonstrating that PDGF-D signaling activates NK cells and enhances IL-15–mediated NK cell survival; cited as foundational data relevant to engineering NK cells with secreted IL-15.
Summary of preclinical work showing freeze-thaw preserved CAR NK cells targeting PSCA prolonged survival in mouse models of metastatic pancreatic cancer.
Licensed CAR NK cell technologies and patent applications from an academic research center to develop an NK cell therapy portfolio.